Universidad Peruana Cayetano Heredia

Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru

Mostrar el registro sencillo del ítem

dc.contributor.author Villasis Mayuri, Elizabeth Melisa
dc.contributor.author Lopez-Perez, M.
dc.contributor.author Torres Fajardo, Katherine Jessica
dc.contributor.author Gamboa Vilela, Dionicia Baziliza
dc.contributor.author Neyra, V.
dc.contributor.author Bendezu, J.
dc.contributor.author Tricoche, N.
dc.contributor.author Lobo, C.
dc.contributor.author Vinetz, Joseph Michael
dc.contributor.author Lustigman, S.
dc.date.accessioned 2022-01-18T19:34:36Z
dc.date.available 2022-01-18T19:34:36Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/11044
dc.description.abstract Background: Erythrocyte invasion by Plasmodium falciparum is a complex process that involves two families; Erythrocyte Binding-Like (EBL) and the Reticulocyte Binding-Like (PfRh) proteins. Antibodies that inhibit merozoite attachment and invasion are believed to be important in mediating naturally acquired immunity and immunity generated by parasite blood stage vaccine candidates. The hypotheses tested in this study were 1) that antibody responses against specific P. falciparum invasion ligands (EBL and PfRh) differ between symptomatic and asymptomatic individuals living in the low-transmission region of the Peruvian Amazon and 2), such antibody responses might have an association, either direct or indirect, with clinical immunity observed in asymptomatically parasitaemic individuals. Methods. ELISA was used to assess antibody responses (IgG, IgG1 and IgG3) against recombinant P. falciparum invasion ligands of the EBL (EBA-175, EBA-181, EBA-140) and PfRh families (PfRh1, PfRh2a, PfRh2b, PfRh4 and PfRh5) in 45 individuals infected with P. falciparum from Peruvian Amazon. Individuals were classified as having symptomatic malaria (N=37) or asymptomatic infection (N=8). Results: Antibody responses against both EBL and PfRh family proteins were significantly higher in asymptomatic compared to symptomatic individuals, demonstrating an association with clinical immunity. Significant differences in the total IgG responses were observed with EBA-175, EBA-181, PfRh2b, and MSP119 (as a control). IgG1 responses against EBA-181, PfRh2a and PfRh2b were significantly higher in the asymptomatic individuals. Total IgG antibody responses against PfRh1, PfRh2a, PfRh2b, PfRh5, EBA-175, EBA-181 and MSP119 proteins were negatively correlated with level of parasitaemia. IgG1 responses against EBA-181, PfRh2a and PfRh2b and IgG3 response for PfRh2a were also negatively correlated with parasitaemia. Conclusions: These data suggest that falciparum malaria patients who develop clinical immunity (asymptomatic parasitaemia) in a low transmission setting such as the Peruvian Amazon have antibody responses to defined P. falciparum invasion ligand proteins higher than those found in symptomatic (non-immune) patients. While these findings will have to be confirmed by larger studies, these results are consistent with a potential role for one or more of these invasion ligands as a component of an anti-P. falciparum vaccine in low-transmission malaria-endemic regions. en_US
dc.language.iso eng
dc.publisher BioMed Central
dc.relation.ispartofseries Malaria Journal
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Peru en_US
dc.subject controlled study en_US
dc.subject major clinical study en_US
dc.subject disease transmission en_US
dc.subject Malaria en_US
dc.subject parasite transmission en_US
dc.subject unclassified drug en_US
dc.subject Plasmodium falciparum en_US
dc.subject school child en_US
dc.subject Immunoglobulin G en_US
dc.subject Parasitemia en_US
dc.subject Malaria, Falciparum en_US
dc.subject Antibodies, Protozoan en_US
dc.subject antibody response en_US
dc.subject immunity en_US
dc.subject Protozoan Proteins en_US
dc.subject enzyme linked immunosorbent assay en_US
dc.subject ligand en_US
dc.subject correlational study en_US
dc.subject Antibodies en_US
dc.subject Erythrocytes en_US
dc.subject membrane protein en_US
dc.subject Ligands en_US
dc.subject erythrocyte binding like protein en_US
dc.subject immunoglobulin G1 antibody en_US
dc.subject immunoglobulin G3 en_US
dc.subject Invasion en_US
dc.subject merozoite en_US
dc.subject Models, Immunological en_US
dc.subject reticulocyte binding like protein en_US
dc.subject species invasion en_US
dc.title Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1186/1475-2875-11-361
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06
dc.relation.issn 1475-2875


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas